50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer

Published:2014-05 Issue:34 Volume: Page:177-189
ISSN:1548-8748
Container-title:American Society of Clinical Oncology Educational Book
language:en
Short-container-title:American Society of Clinical Oncology Educational Book

Author:

Wakelee Heather¹,Kelly Karen¹,Edelman Martin J.¹

Affiliation:

1. From the Stanford Cancer Institute, Stanford University, Stanford, CA; University of California, Davis Cancer Center, Sacramento, CA; University of New Mexico Cancer Center, Albuquerque, NM.

Abstract

Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

Link

https://ascopubs.org/doi/pdfdirect/10.14694/EdBook_AM.2014.34.177

Reference105 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

2. A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer

3. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1

4. Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

5. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment;Cancer Research Communications;2024-03-26

2. Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma;Cancers;2024-02-10

3. Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024);RSC Medicinal Chemistry;2024

4. Epigenetic regulation in lung cancer;MedComm;2023-10-26

5. Anticancer Effects and Molecular Mechanisms of Gossypin on Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibition in Human Nonsmall Cell Lung Cancer Cell Line, A549;Natural Product Communications;2023-08